Eli Lilly announces results of direct comparative clinical trial for obesity treatment
Clinical trial results showed that American pharmaceutical company Eli Lilly’s obesity treatment drug ‘Zebbound’ showed a greater weight loss effect than its competitor, Denmark’s Novo nordisk’s obesity treatment ‘WeGobee’.
Eli Lilly announced on the 4th (local time) that as a result of a head-to-head trial directly comparing zebbound with WeGobee, the weight loss effect was 47% better than WeGoBe.
This is the topline (main indicator) result of a phase 3b clinical trial (clinical name: SURMOUNT-5) that compared the treatment effects of Zebbound and Wigobi in obese adult patients without diabetes.
As an inevitable result of the study, patients using zebbound lost an average of 50.3 pounds (22.8 kg) after 72 weeks, and patients using Wegobi lost an average of 33.1 pounds (15.0 kg). it was explained that on average, Zebbound lost 20.2%, showing a 47% greater weight loss compared to 13.7% for WeGobee.
In the secondary evaluation index, 31.6% of patients taking Zebbound achieved weight loss of at least 25%, while 16.1% of patients taking Wegobi achieved weight loss.
“We are pleased that Zebbound helped people achieve 47% more weight loss compared to WeGobee,” said Dr. Leonard Glass, Vice President of Global Medical Affairs at Eli Lilly.“Zebbound is the only dual GIP/GLP-1 receptor approved by the U.S. FDA. It is in a unique position as an agonist obesity drug. “We are changing the way millions of people manage this chronic disease.”
The overall safety profile (trend) appeared similar to previously reported clinical trials. The most commonly reported side effects for both Zebbound and WeGobee were gastrointestinal side effects.
Lilly plans to continue evaluating SURMOUNT-5 results.
Zebbound (ingredient name: terzepatide) is a dual agonist that acts on both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). WeGobee (semaglutide) has a single action on the GLP-1 receptor and was launched in the United States in 2021, about two years earlier than Zebbound.
[서울=뉴시스]
rnrn
-
- great
- 0dog
-
- I’m sad
- 0dog